Medline Inc.
MDLN Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$33.69
KIRA · Stoqly’s AI analyst, in plain words
- Medline Inc. had $28.4B of revenue in fiscal 2025, up 11.5% on the year before.
- Its operating margin was 7.8%, down 0.6 pts: of every 100 in sales, about 8 is left after running the business.
- Medline Inc. made $1.2B of net profit in fiscal 2025.
- Free cash flow was $1.3B in fiscal 2025, 4.6% of revenue.
- Medline Inc. returned $33.0M to shareholders in fiscal 2025, 3% of free cash flow.
- Medline Inc. owes $10.6B more than it holds in cash, about 3.3 years of operating profit.
Market cap
$29.0B
P/E
—
Revenue
$28.4B
Net income
$1.2B
Free cash flow
$1.3B
Operating margin
7.8%
Medline Inc. in 30 seconds · fiscal 2025
Are sales growing?
+11.5%
Yes. Sales grew 11.5% last year.
Does it make a profit?
4.1%
A little. It keeps 4.1% of every sale as profit.
Does profit turn into cash?
4.6%
Partly. 4.6% of sales ends up as free cash.
Is debt under control?
3.3x
Heavy. Repaying its debt would take 3.3 years of operating profit.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Medline Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Medline Inc.
- CIK
- 0002046386
Medline Inc. · MDLN
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $23.2B | $25.5B | $28.4B |
| Revenue growth | — | 9.8% | 11.5% |
| Gross margin | 25.3% | 27.3% | 26.4% |
| Operating margin | 5.4% | 8.4% | 7.8% |
| Net income | $234M | $1.2B | $1.2B |
| Net margin | 1.0% | 4.6% | 4.1% |
| Diluted EPS | — | — | −$0.01 |
| Cash | |||
| Cash from operations | $1.7B | $1.8B | $1.7B |
| Capital expenditure | $275M | $354M | $447M |
| Free cash flow | $1.4B | $1.4B | $1.3B |
| FCF margin | 6.1% | 5.5% | 4.6% |
| Share buybacks | $0.0M | $20.0M | $33.0M |
| Debt and strength | |||
| Cash and short-term investments | $1.6B | $199M | $1.9B |
| Debt incl. finance leases | — | $16.5B | $12.6B |
| Shareholders' equity | — | — | $10.7B |
| Net debt / EBITDA | — | 5.2x | 3.3x |
| Current ratio | — | 3.4x | 4.3x |
| Interest coverage | 1.0x | 1.9x | 2.3x |
| Returns and quality | |||
| Return on capital | — | — | 9.6% |
| Return on equity | — | — | 10.8% |
| Piotroski F-score | — | — | 6 |
| Altman Z'' | — | — | 2.4 |
Insiders bought, 12 months
$515M
4 insiders
Insiders sold, 12 months
$8.2B
11 insiders
Of sales under plans
0%
$3.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Medline Inc. · MDLN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $33.69 a share, the company is worth $29.0B.
Source: SEC EDGAR XBRL filings (CIK 0002046386). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.